2 days ago
1
jetcityimage/iStock Editorial via Getty Images
Eli Lilly (NYSE:LLY) shares slipped ~12% in the premarket on Thursday after the company disclosed topline data from a late-stage trial for its oral GLP-1 receptor agonist orforglipron targeting obese or overweight adults.
Novo Nordisk (NVO), LLY’s main rival
English (US) ·